1058 GMT - EssilorLuxottica's purchase of Cellview Imaging marks the second acquisition in ophthalmology diagnostics for the European eyecare giant as it pushes into this and other subcategories, RBC Capital Markets' Piral Dadhania says in a note. The Ray-Ban maker said it is buying Canadian startup Cellview, which offers diagnostics via retinal imaging, for an undisclosed sum. The deal follows EssilorLuxottica's July acquisition of Heidelberg Engineering, another ophthalmology diagnostics company, and strengthens its offering, RBC says. EssilorLuxottica is pursuing a structural expansion into selective ophthalmology subcategories, with a move into diagnostics already in progress and potentially in cataracts and contact lenses down the line, the analyst says. Shares rise 1.1%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
February 11, 2025 05:58 ET (10:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。